Peripheral Neuropathy Clinical Trial
Official title:
A Randomized, Four-Arm Study Comparing Reiki, Yoga, Meditation, or Patient Education Group for Addressing Symptoms of Chemotherapy-Induced Peripheral Neuropathy (CIPN)
Verified date | April 2012 |
Source | George Mason University |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
The purpose of this study is to test whether people with symptoms of chemotherapy-induced peripheral neuropathy (CIPN) receive physical or psychological benefits from participating in a six-week Reiki, Yoga, Meditation, or Educational experience.
Status | Completed |
Enrollment | 36 |
Est. completion date | March 2012 |
Est. primary completion date | July 2010 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years to 90 Years |
Eligibility |
Inclusion Criteria: - participants must be of at least 18 years of age, - participants must have persistent symptoms of CIPN resulting from treatment with vinca alkaloid, taxane, platinum class chemotherapies or immunomodulators (Thalidomide) or antineoplastic agents (Velcade) for a known cancer diagnosis - participants must have completed chemotherapy at least three months prior to beginning the study, - participants cannot concurrently receive chemotherapy treatment for cancer, nor - actively take part in one of the complementary modalities offered in this pilot study. - participants will be required to have an ability to comfortably speak, read, and understand English. - participants must be fully oriented and possess the capacity to understand and provide informed consent for participation in the study. Exclusion Criteria: - failure to meet any one of the inclusion criteria |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care
Country | Name | City | State |
---|---|---|---|
United States | Life with Cancer Family Center | Fairfax | Virginia |
Lead Sponsor | Collaborator |
---|---|
George Mason University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | FACT GOG-ntx scale | This scale measures two outcomes:symptoms of neurotoxicity and quality of life. The FACT GOG-ntx combines the 27-item general Functional Assessment of Cancer Therapy scale (FACT-G) with an 11-item neurotoxicity subscale. Completion of the FACT-G does not require assistance and can be completed in less than five minutes. Cronbach's coefficient for each item on this scale has been demonstrated at 0.70 or higher, and the instrument is sensitive to respondent changes over time. | change from baseline in quality of life and symptoms of neurotoxicity in 6 weeks | No |
Secondary | The Brief Symptom Inventory - 18 (BSI-18) | The BSI-18 is an 18-item brief psychological screening instrument that has been designed to measure distress and yields a global distress score as well as subscale scores for somatic concerns, anxiety, and depression. The BSI-18 has been found to have good internal reliability with a Cronbach's alpha value of 0.89 | change from baseline in quality of life and symptoms of neurotoxicity in 6 weeks | No |
Secondary | Mindful Attention Awareness scale (MAAS) | The MAAS is a 15-item scale that is self-administered, requires no assistance to complete, and can be taken in five minutes or less. The instrument was developed to evaluate states of mindfulness or the respondent's capacity to simply observe and be aware of internal and external events in the present moment as a method of self-regulation. Internal reliability of items on the MAAS has been established with Cronbach's Alpha coefficients at 0.80 or higher per item. | change from baseline in quality of life and symptoms of neurotoxicity in 6 weeks | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05152368 -
Safety of Cultured Allogeneic Adult Umbilical Cord Stem Cells for Trigeminal Neuralgia and Peripheral Neuropathy
|
Phase 1 | |
Completed |
NCT05647083 -
The Effect of Massage on Diabetic Parameters
|
N/A | |
Completed |
NCT02549534 -
Early Detection of Taxane-Induced Neuropathy in Women With Breast Cancer
|
N/A | |
Active, not recruiting |
NCT02701075 -
MC5-A Scrambler Therapy for the Treatment of Chronic Neuropathic Extremity Pain
|
N/A | |
Completed |
NCT01196442 -
Electrical Stimulation Pain Therapy in Treating Chronic Pain and Numbness Caused By Chemotherapy in Patients With Cancer
|
N/A | |
Completed |
NCT00763087 -
Effect of Weight-Bearing Exercise on People With Diabetes and Neuropathic Feet
|
N/A | |
Completed |
NCT00079807 -
Painful HIV Neuropathy and Alpha-Lipoic Acid
|
Phase 1/Phase 2 | |
Completed |
NCT03292328 -
Yoga for Symptoms of Nerve Damage Caused by Chemotherapy
|
N/A | |
Active, not recruiting |
NCT05379140 -
Use Therapeutic Chinese Massage to Treat Peripheral Neuropathy in People With HIV
|
N/A | |
Recruiting |
NCT05673746 -
Acupuncture in Chemotherapy-induced Peripheral Neuropathy in Women With Breast Cancer
|
N/A | |
Completed |
NCT05189535 -
"Prevention of Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients"
|
Phase 2/Phase 3 | |
Recruiting |
NCT06219590 -
Acetylcholine Iontophoresis As A New Challenge With Type 2 Diabetic Peripheral Neuropathy: A Possible New Therapy
|
N/A | |
Enrolling by invitation |
NCT05595109 -
Role of Silymarin in Chemotherapy Toxicity and Cognition Improvement in Breast Cancer Patients
|
Phase 2/Phase 3 | |
Completed |
NCT05916118 -
Exercise and Oxaliplatin-induced Peripheral Neuropathy
|
N/A | |
Withdrawn |
NCT03881748 -
Clinical Trial of Acupuncture for Chemotherapy-Induced Peripheral Neuropathy
|
N/A | |
Not yet recruiting |
NCT03112057 -
Visualize Nociceptor Changes in Neuropathic Human
|
N/A | |
Completed |
NCT02936843 -
Targeting Inflammation With Salsalate in Type 1 Diabetes Neuropathy
|
Phase 2/Phase 3 | |
Terminated |
NCT01458015 -
Tapentadol Versus Oxycodon - a Mechanism-based Treatment Approach in Neuropathic Pain
|
Phase 4 | |
Completed |
NCT01006408 -
Treatment Trial Using Low Level Laser Therapy (LLLT) for Treatment of Chemotherapy Induced Peripheral Neuropathy
|
N/A | |
Completed |
NCT00471445 -
Topical Amitriptyline and Ketamine Cream in Treating Peripheral Neuropathy Caused by Chemotherapy in Cancer Patients
|
Phase 3 |